Loading the session
Loading the session
Loading instrument
$109.75
+26.97%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 close of $110.68 was 14.9% above its 50-day average ($96.29) and 14.1% above its 200-day average ($96.99). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed below the 200-day on 2 Nov 2026, 2 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 4 Nov 2026 gain of 28.0% was 12.8× its average daily move of 2.2% over the past year, and its largest one-day gain since 9 Jul 2025.
Daily closes, split-adjusted · as of 4 Nov 2026
4 Nov 2026 volume of 5.5M shares was 5.8× the average of the 30 sessions before it (952.8K), as the price rose 28.0%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
10.8M shares were sold short at the 30 Sep 2026 settlement, 15.7% of the 68.5M shares outstanding; covering them would take 14.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 30 Sep 2026
1 month: +21.9% (SPY −1.6%, XLV +13.5%). 3 months: 0.0% (SPY −0.4%, XLV +15.5%). 1 year: +5.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RYTM, SPY and XLV · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
July 9, 2025
+36.63%July 13, 2022
+31.48%July 12, 2022
+42.22%